专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006034292A3 ANTIBODIES AGAINST AND METHODS FOR PRODUCING VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS 审中-公开
标题翻译：抗生素抗生素和生产呼吸道感染病毒疫苗的方法
公开(公告)号：WO2006034292A3
公开(公告)日：2009-04-16
申请号：PCT/US2005033705
申请日：2005-09-21
申请人： MEDIMMUNE INC , TOUS GUILLERMO , SCHENERMAN MARK , CASAS-FINET JOSE , WEI ZIPING , PFARR DAVID
发明人： TOUS GUILLERMO , SCHENERMAN MARK , CASAS-FINET JOSE , WEI ZIPING , PFARR DAVID
IPC分类号： G01N33/53
CPC分类号： A61K39/155 , A61K39/00 , A61K2039/505 , A61K2039/6081 , C07K14/005 , C07K16/1027 , C07K2317/55 , C07K2317/92 , C12N7/00 , C12N2760/18522 , C12N2760/18534 , G01N33/6854 , G01N2333/135
摘要： The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
摘要翻译：本发明涉及新型呼吸道合胞病毒（RSV）F肽及其组合物。本发明还涉及评估结合F肽的抗RSV抗体的方法。本发明还涉及免疫特异性结合本发明的F肽的抗体。本发明还提供了用于预防，中和，治疗RSV感染的F肽和/或免疫特异性结合F肽的抗体的方法和方案。此外，本发明的方法可用于治疗，预防和改善与RSV感染相关的症状。

2. 发明申请

WO2008121615A3 ANTIBODY FORMULATION 审中-公开
标题翻译：抗体配方
公开(公告)号：WO2008121615A3
公开(公告)日：2008-12-04
申请号：PCT/US2008058132
申请日：2008-03-25
申请人： MEDIMMUNE INC , BISHOP STEVEN , WOLFORD JENNY S
发明人： BISHOP STEVEN , WOLFORD JENNY S
IPC分类号： A61K39/395 , C07K16/00 , C07K16/24
CPC分类号： C07K16/249 , A61K9/0019 , A61K9/08 , A61K39/3955 , A61K39/39591 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/22 , A61K47/26 , A61K47/34 , A61K47/36 , A61K2039/505 , C07K2317/14 , C07K2317/40
摘要： The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide.
摘要翻译：本发明提供了与人干扰素α多肽特异性结合的抗体或其片段的高浓度液体制剂。

3. 发明申请

WO2008121616A3 ANTIBODIES WITH DECREASED DEAMIDATION PROFILES 审中-公开
公开(公告)号：WO2008121616A3
公开(公告)日：2008-10-09
申请号：PCT/US2008/058133
申请日：2008-03-25
申请人： MEDIMMUNE, INC. , RAM, Kripa , VENKAT, Raghavan
发明人： RAM, Kripa , VENKAT, Raghavan
IPC分类号： A61K39/395 , C12N5/04
摘要： The present invention relates to antibodies with decreased deamidation profiles, and methods for producing antibodies with decreased deamidation profiles.

4. 发明申请

WO2008100816A2 ANTIBODY DISPLAY 审中-公开
标题翻译：抗体显示
公开(公告)号：WO2008100816A2
公开(公告)日：2008-08-21
申请号：PCT/US2008053398
申请日：2008-02-08
申请人： MEDIMMUNE INC , WU HERREN , GAO CHANGSHOU
发明人： WU HERREN , GAO CHANGSHOU
IPC分类号： C40B40/10
CPC分类号： C40B30/04 , C07K16/00 , C07K16/2866 , C07K2317/24 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C12N15/1037 , C40B40/06 , C40B40/10
摘要： The present invention relates to antibodies or antibody fragments that may be displayed on the extracellular surface of the plasma membrane when expressed in a host cell. The present invention provides libraries comprising a plurality of plasma membrane displayed antibodies and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
摘要翻译：本发明涉及当在宿主细胞中表达时可显示在细胞膜表面的抗体或抗体片段。本发明提供了包含多个质膜显示的抗体的文库，以及筛选具有所需特征的抗体或抗体片段的文库的方法。

5. 发明申请

WO2007103470A2 HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE 审中-公开
标题翻译：人类抗CD22抗体及其在治疗肿瘤，移植和自发性疾病中的应用
公开(公告)号：WO2007103470A2
公开(公告)日：2007-09-13
申请号：PCT/US2007005884
申请日：2007-03-06
申请人： MEDIMMUNE INC , AERES BIOMEDICAL LTD , HILBERT DAVID , JONES TARRAN , WILLIAMS DAVID G
发明人： HILBERT DAVID , JONES TARRAN , WILLIAMS DAVID G
IPC分类号： A61K39/395 , C07H21/04 , C07K16/18
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/465 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ("VH") and four human or humanized framework regions of the immunoglobulin light chain variable region ("VK"). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft- versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
摘要翻译：本发明提供抗CD22小鼠单克隆抗体HB22.7的嵌合和人源化形式。本发明的抗CD22抗体包含免疫球蛋白重链可变区（“VH”）和免疫球蛋白轻链可变区（“VK”）的四个人或人源化框架区的四个人或人源化框架区。本发明还包含含有一个或多个反向突变的重链和/或轻链FW区，其中人FW残基被交换为亲本小鼠重链或轻链中存在的相应残基。本发明抗体的人源化或人源化VH框架区可以包含一个或多个以下残基：构架区1的位置24的缬氨酸（V），构架区2的位置49处的甘氨酸（G）和天冬酰胺（N）在框架区域3的位置73，根据Kabat编号。本发明进一步涉及药物组合物，免疫治疗组合物和使用结合人CD22抗原并且优选介导人ADCC，CDC和/或细胞凋亡的治疗性抗体的方法：治疗人类受试者的B细胞疾病和病症，例如但不限于B细胞恶性肿瘤，用于治疗和预防自身免疫性疾病，以及用于治疗和预防移植物抗宿主病（GVHD），体液排斥和移植后淋巴增生性疾病的人类移植收件人。

6. 发明申请

WO2007005612A3 AN INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTICS 审中-公开
公开(公告)号：WO2007005612A3
公开(公告)日：2007-01-11
申请号：PCT/US2006/025590
申请日：2006-06-30
申请人： MEDIMMUNE, INC. , ALLAN, Christian , WU, Herren , SWERS, Jeffery , DALL'ACQUA, William
发明人： ALLAN, Christian , WU, Herren , SWERS, Jeffery , DALL'ACQUA, William
IPC分类号： A61K51/10
摘要： The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics.

7. 发明申请

WO2007001422A3 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2007001422A3
公开(公告)日：2007-01-04
申请号：PCT/US2005/037734
申请日：2005-10-21
申请人： MEDIMMUNE, INC. , WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
发明人： WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
IPC分类号： A61K39/395 , G01N33/53
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

8. 发明申请

WO2007001422A2 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
标题翻译： HMGB1的高亲和力抗体及其使用方法
公开(公告)号：WO2007001422A2
公开(公告)日：2007-01-04
申请号：PCT/US2005037734
申请日：2005-10-21
申请人： MEDIMMUNE INC , WU HERREN , ALLAN CHRISTIAN B , GAO CHANGSHOU , AN LING-LING , KIENER PETER , MAO SU-YAU , COYLE ANTHONY
发明人： WU HERREN , ALLAN CHRISTIAN B , GAO CHANGSHOU , AN LING-LING , KIENER PETER , MAO SU-YAU , COYLE ANTHONY
IPC分类号： A61K39/395 , C07K16/40
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
摘要翻译：公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血症内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。此外，本发明的高亲和力抗体可用作诊断抗体。

9. 发明申请

WO2006116260A2 MODULATION OF ANTIBODY EFFECTOR FUNCTION BY HINGE DOMAIN ENGINEERING 审中-公开
标题翻译：通过兴奋剂工程调整抗体效应函数
公开(公告)号：WO2006116260A2
公开(公告)日：2006-11-02
申请号：PCT/US2006/015393
申请日：2006-04-25
申请人： MEDIMMUNE, INC. , DALL'ACQUA, William , WU, Herren , DAMSCHRODER, Melissa , CASA-FINET, Jose
发明人： DALL'ACQUA, William , WU, Herren , DAMSCHRODER, Melissa , CASA-FINET, Jose
IPC分类号： C12P21/06 , C07K16/44
CPC分类号： C07K16/18 , C07K16/00 , C07K16/2866 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
摘要翻译：本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改变Fc与一个或多个Fc配体（例如FcγR）的结合和/或调节效应子功能。更具体地，本发明提供了对一种或多种FcγR和/或C1q具有修饰的结合亲和力的Fc变体。另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。

10. 发明申请

WO2006050346A2 ULTRA HIGH THROUGHPUT CAPTURE LIFT SCREENING METHODS 审中-公开
标题翻译：超高速抽出式抽出式筛选方法
公开(公告)号：WO2006050346A2
公开(公告)日：2006-05-11
申请号：PCT/US2005039436
申请日：2005-10-31
申请人： MEDIMMUNE INC , WU HERREN , GAO CHANGSHOU
发明人： WU HERREN , GAO CHANGSHOU
IPC分类号： C40B40/10
CPC分类号： C12N15/1037 , C12N15/1058 , C12N15/1086 , C40B30/04
摘要： The present invention relates to a method for identification and isolation of binding molecules having a selective affinity for a ligand. More specifically, this invention provides a process for the ultra high throughput screening of binding molecules from expression libraries containing billions of independent clones without the biases and limitations of other high throughput screening methods such as panning. Additionally, the present invention provides a method for the production of expression libraries essentially free of clones encoding non-functional molecules.
摘要翻译：本发明涉及用于鉴定和分离对配体具有选择性亲和性的结合分子的方法。更具体地，本发明提供了一种从含有数十亿独立克隆的表达文库中超结合分子的超高通量筛选方法，而没有其他高通量筛选方法（如平移）的偏差和限制。另外，本发明提供了生产基本上不含编码非功能性分子的克隆的表达文库的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式